Indaptus Therapeutics logo

Indaptus TherapeuticsNASDAQ: INDP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 August 2015

Next earnings report:

13 March 2025

Last dividends:

N/A

Next dividends:

N/A
$11.93 M
-77%vs. 3y high
20%vs. sector
-vs. 3y high
-vs. sector
-46%vs. 3y high
57%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 00:52:13 GMT
$1.17+$0.03(+2.63%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

INDP Latest News

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
globenewswire.com11 November 2024 Sentiment: POSITIVE

Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapy Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapy

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
globenewswire.com23 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor conferences:

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewsWire06 September 2023 Sentiment: POSITIVE

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel.

What type of business is Indaptus Therapeutics?

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

What sector is Indaptus Therapeutics in?

Indaptus Therapeutics is in the Healthcare sector

What industry is Indaptus Therapeutics in?

Indaptus Therapeutics is in the Biotechnology industry

What country is Indaptus Therapeutics from?

Indaptus Therapeutics is headquartered in United States

When did Indaptus Therapeutics go public?

Indaptus Therapeutics initial public offering (IPO) was on 04 August 2015

What is Indaptus Therapeutics website?

https://indaptusrx.com

Is Indaptus Therapeutics in the S&P 500?

No, Indaptus Therapeutics is not included in the S&P 500 index

Is Indaptus Therapeutics in the NASDAQ 100?

No, Indaptus Therapeutics is not included in the NASDAQ 100 index

Is Indaptus Therapeutics in the Dow Jones?

No, Indaptus Therapeutics is not included in the Dow Jones index

When was Indaptus Therapeutics the previous earnings report?

No data

When does Indaptus Therapeutics earnings report?

The next expected earnings date for Indaptus Therapeutics is 13 March 2025